Logo

American Heart Association

  17
  0


Final ID: MP1677

Proteomic and Phosphoproteomic Profiling of Cardiac Left Ventricular Tissue from an Animal Model of Early Stage Heart Failure with Preserved Ejection Fraction after Soluble Guanylate Cyclase Stimulation

Abstract Body (Do not enter title and authors here): Introduction/Background: Stimulation of soluble guanylate cyclase (sGC) represents a promising pharmacological strategy in the treatment of heart failure with reduced ejection fraction, but it has not been proved yet to be efficacious in heart failure with preserved ejection fraction (HFpEF).
Research Questions/Hypothesis: Our aim was to clarify the molecular pathways involved in the cardiac effects of sGC stimulation in a preclinical model of early-stage HFpEF through the analysis of proteomic/phosphoproteomic profiles.
Methods/Approach: Male obese ‘Zucker fatty and spontaneously hypertensive’ (ZSF1) rats (n=10) were treated at 14 weeks of age for 4 weeks with the sGC stimulator vericiguat at 3 mg/kg/p.o. once daily. Control groups (obese and lean ZSF1 rats, n=10) received vehicle. Echocardiographic evaluation was performed at 17 weeks of age. Oxygen consumption rate of left ventricle mitochondria was assessed by high-resolution respirometry. Left ventricle tissue samples were examined under electron microscopy, and proteomic/phosphoproteomic profiling was performed on a TripleTOF® 6600 LC-MS/MS system. Statisticals: Mann-Whitney/Chi-squared Tests.
Results/Data: sGC stimulation improved diastolic function in treated rats, markedly enhancing cardiac mitochondrial respiration and cristae organization. Proteomic analysis comparing obese treated group vs. obese control group determined statistically significant differences of 88 proteins in left ventricular tissue. Treatment boosted biological processes related to mitochondrial function, oxidative phosphorylation, respiratory electron chain or generation of ATP, and decreased myofibrillar remodeling pathways. Phosphoproteomic profile revealed 49 phosphoproteins whose levels were significantly different between groups. Treatment increased phosphoproteins involved in pentose phosphate shunt, and small molecule, carboxylic, lipid and monocarboxyl acid catabolic pathways, while diminished those correlated with cytoskeleton-dependent cytokinesis, protein folding and organelle, membrane and vesicle fusion processes.
Conclusion(s): Our data provides molecular insights into the potential role of sGC stimulation in regulating cardiac mitochondrial respiration and cristae morphology in early-stage HFpEF. Several relevant changes in proteomic/phosphoproteomic profiles define the mitochondrial respirasome as the biological process most affected at cardiac level after sGC stimulation.
  • Vázquez-abuín, Xocas  ( IDIS, Complexo Hospitalario Universitario de Santiago de Compostela, Área Sanitaria Santiago de Compostela e Barbanza (SERGAS) , Santiago de Compostela , Spain )
  • Goncalves, Alexandre  ( Cardiovascular R&D Centre - UnIC@RISE, Faculty of Medicine, University of Porto , Porto , Portugal )
  • Pereira Morais, Juliana  ( CINTESIS@RISE, NOVA Medical School|Faculdade de Ciências Médicas, NMS|FCM, Universidade Nova de Lisboa, UnIC@RISE - Cardiovascular Research Centre, Faculdade de Medicina, Universidade do Porto , Porto , Portugal )
  • Alves, Ines N  ( Cardiovascular R&D Centre - UnIC@RISE, Faculty of Medicine, University of Porto , Porto , Portugal )
  • Sousa-mendes, Claudia  ( Cardiovascular R&D Centre - UnIC@RISE, Faculty of Medicine, University of Porto , Porto , Portugal )
  • Pires, Inês  ( Cardiovascular R&D Centre - UnIC@RISE, Faculty of Medicine, University of Porto , Porto , Portugal )
  • GonzÁlez-juanatey, Jose RamÓn  ( IDIS, Complexo Hospitalario Universitario de Santiago de Compostela, Área Sanitaria Santiago de Compostela e Barbanza (SERGAS) , Santiago de Compostela , Spain )
  • Feijoo-bandin, Sandra  ( IDIS, Complexo Hospitalario Universitario de Santiago de Compostela, Área Sanitaria Santiago de Compostela e Barbanza (SERGAS) , Santiago de Compostela , Spain )
  • Lago, Maria Francisca  ( IDIS, Complexo Hospitalario Universitario de Santiago de Compostela, Área Sanitaria Santiago de Compostela e Barbanza (SERGAS) , Santiago de Compostela , Spain )
  • Morana-fernandez, Sandra  ( IDIS, Complexo Hospitalario Universitario de Santiago de Compostela, Área Sanitaria Santiago de Compostela e Barbanza (SERGAS) , Santiago de Compostela , Spain )
  • Aragon-herrera, Alana  ( IDIS, Complexo Hospitalario Universitario de Santiago de Compostela, Área Sanitaria Santiago de Compostela e Barbanza (SERGAS) , Santiago de Compostela , Spain )
  • Sandner, Peter  ( Bayer AG , Wuppertal , Germany )
  • Thomitzek, Karen  ( BAYER AG , Berlin , Germany )
  • Garcia-seara, Francisco Javier  ( IDIS, Universidade de Santiago de Compostela , Santiago de Compostela , Spain )
  • Bravo, Susana B  ( Health Research Institute of Santiago de Compostela (IDIS) , Santiago de Compostela , Spain )
  • Otero-santiago, Manuel Francisco  ( Área Sanitaria Santiago de Compostela e Barbanza (SERGAS) , Santiago de Compostela , Spain )
  • Rodrigues, Alexandre  ( Cardiovascular R&D Centre - UnIC@RISE, Faculty of Medicine, University of Porto , Porto , Portugal )
  • Author Disclosures:
    Xocas Vazquez-Abuin: DO NOT have relevant financial relationships | Alexandre Goncalves: No Answer | Juliana Pereira Morais: No Answer | Ines N Alves: No Answer | Claudia Sousa-Mendes: No Answer | Inês Pires: DO NOT have relevant financial relationships | JOSE RAMÓN GONZÁLEZ-JUANATEY: No Answer | Sandra Feijoo-Bandin: No Answer | Maria Francisca Lago: No Answer | Sandra Morana-Fernandez: No Answer | Alana Aragon-Herrera: DO NOT have relevant financial relationships | Peter Sandner: DO NOT have relevant financial relationships | Karen Thomitzek: No Answer | Francisco Javier Garcia-Seara: No Answer | Susana B Bravo: No Answer | Manuel Francisco Otero-Santiago: No Answer | Alexandre Rodrigues: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Novel Therapies and Molecular Targets in Heart Failure with Preserved Ejection Fraction

Sunday, 11/09/2025 , 03:15PM - 04:30PM

Moderated Digital Poster Session

More abstracts on this topic:
Age-Related Impairment of Mitochondrial Protein Turnover Exacerbates Pathogenesis of Heart Failure with Preserved Ejection Fraction in Old Mice

Kobak Kamil, Zarzycka Weronika, King Catherine, Borowik Agnieszka, Peelor Frederick, Kinter Michael, Miller Benjamin, Chiao Ying Ann

Biodistribution of Systemically Administered Lab-grown, 3D Extracellular Matrix Particles and Their Effects on Post-Myocardial Infarction Cardiac Function

Broadwin Mark, Abid Ruhul, St Angelo Katerina, Petersen Max, Brinck Teixeira Rayane, Harris Dwight, Stone Christopher, Xu Cynthia, Sellke Frank, Morgan Jeffrey

You have to be authorized to contact abstract author. Please, Login
Not Available